MarketLens
Sign Up
Stock AnalysisInvestment Ideas

What Does the Ligand-XOMA Deal Mean for the Royalty Aggregator Landscape

6 months ago
SHARE THIS ON:

What Does the Ligand-XOMA Deal Mean for the Royalty Aggregator Landscape

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

Already a Pro member? Log in
SHARE THIS ON:

Related Articles

What Does SK Hynix's $8 Billion ASML Deal Mean for the Semiconductor Landscape

What Does SK Hynix's $8 Billion ASML Deal Mean for the Semiconductor Landscape

7 months ago
What Does Global Robotics' Latest Acquisition Mean for the Industrial Automation Landscape

What Does Global Robotics' Latest Acquisition Mean for the Industrial Automation Landscape

5 months ago
What Does Santander's Acquisition of Webster Financial Mean for the U.S. Banking Landscape

What Does Santander's Acquisition of Webster Financial Mean for the U.S. Banking Landscape

7 months ago
What Does FERC Approval Mean for the TXNM Energy-Blackstone Deal

What Does FERC Approval Mean for the TXNM Energy-Blackstone Deal

8 months ago

Category

TopFeaturedPro OnlyStock AnalysisInvestment IdeasETFsCrypto

You may also like

News•2 weeks ago

Xencor: Better Funding For Obexelimab

Xencor's settlement with Alexion improved its cash runway, which should now fund operations through obexelimab's FDA PDUFA decision for IgG4-related disease. Xencor would receive royalties and milesto...
Stock News•3 months ago

Biotech's takeover boom may be running out of buyers

Biotech deal value hit $78B in H1 2026, nearly double 2025's full-year $42B total. RBC Capital Markets warns the pace is unlikely to hold, suggesting a slowdown ahead.
AZN
Stock News•3 months ago

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Ligand completed its ~$739M acquisition of XOMA Royalty at $39/share, creating a portfolio of over 200 biopharmaceutical royalty assets including VABYSMO and OJEMDA.
XOMA

Breaking News

View All →
Biotech & Pharma
Clinical Trials (Phase I, II, III)
Bitcoin (BTC)
Cryptocurrency
Earnings
Event-Driven Investing
Market Crash / Correction

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

2 months ago
Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

2 months ago
Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

2 months ago

Top Headlines

View More →
Stock News•3 hours ago

Elon Musk Just Gave Fantastic News for Nvidia Investors

Stock News•5 hours ago

Peter Thiel says Apple has done 'nothing new' after Steve Jobs

Stock News•8 hours ago

Meet Wall Street's Newest Major Stock Split: It Has Soared 1,730% Since Its 2012 IPO, and There Is Plenty of Upside Left

Stock News•8 hours ago

PC Sales Just Crashed 21% as AI Eats the World's Memory Chips

Stock News•10 hours ago

CrowdStrike's CEO Says a Wave of Cyber Attacks Are Coming